AC
ANTX icon

Almitas Capital’s AN2 Therapeutics ANTX Stock Holding History

Almitas Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.11M Sell
1,469,129
-10,000
-0.7% -$43K 1.7% 12
2026
Q1 		$5.06M Hold
1,479,129
– – 1.14% 20
2025
Q4 		$1.69M Buy
1,479,129
+50,806
+4% +$59.3K 0.37% 45
2025
Q3 		$1.81M Hold
1,428,323
– – 0.42% 37
2025
Q2 		$1.51M Buy
1,428,323
+115,212
+9% +$137K 0.38% 39
2025
Q1 		$1.79M Hold
1,313,111
– – 0.59% 35
2024
Q4 		$1.81M Buy
+1,313,111
New +$1.59M 0.4% 44

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Almitas Capital's ANTX Position: Q2 2026 in Review

Almitas Capital reduced its AN2 Therapeutics (ANTX) stake by 0.68% in Q2 2026, selling an estimated $43K and leaving 1,469,129 shares worth $7.11M. The position accounts for 1.7% of the portfolio, ranked #12.

Almitas Capital first reported a position in ANTX in Q4 2024 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Almitas Capital held 1,469,129 shares of AN2 Therapeutics worth $7.11M as of Q2 2026.
  • Almitas Capital sold 10,000 AN2 Therapeutics shares in Q2 2026, an estimated $43K.
  • AN2 Therapeutics made up 1.7% of Almitas Capital's portfolio in Q2 2026, its #12 holding.
  • Almitas Capital first reported a position in AN2 Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Almitas Capital's 13F filing for Q2 2026, filed 17 Aug 2026.